氨甲环酸治疗老年人轻度创伤性脑损伤的成本效果与信息价值分析以指导未来研究
该研究构建早期经济决策模型,从英国医疗体系视角评估院前使用氨甲环酸治疗70岁及以上轻度创伤性脑损伤成人相对于常规护理的成本效果。基础分析中氨甲环酸增量成本效果比为每获得1个质量调整生命年4885英镑,但具有成本效果的可能性高度依赖于全因死亡率治疗效果。
要点
- 氨甲环酸治疗老年人轻度创伤性脑损伤的成本效果存在高度不确定性。
- 基础分析增量成本效果比为每QALY 4885英镑,但高度依赖全因死亡率效应。
核心结论
- 氨甲环酸用于老年人轻度创伤性脑损伤的成本效果存在高度不确定性,意味着在英国开展未来研究具有很高价值。
- 全球背景下的价值可能远高于此。
研究设计与样本
- 早期经济决策模型,比较70岁及以上轻度创伤性脑损伤成人接受常规护理与加用氨甲环酸的效果。
- 从英国医疗体系视角,采用终身时间范围,成本以2020年英镑报告,结局以质量调整生命年报告。
- 所有分析采用每QALY 20000英镑的成本效果阈值。
主要发现
- 基础分析中,氨甲环酸增量成本效果比为每获得1个QALY 4885英镑,但具有成本效果的可能性高度依赖于全因死亡率治疗效果。
- 氨甲环酸的全因死亡率风险比和创伤性脑损伤后功能结局对成本效果影响最大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid reduces head injury deaths in patients with CT scan evidence of intracranial bleeding after mild traumatic brain injury (TBI). However, the cost-effectiveness of tranexamic acid for people with mild TBI in the pre-hospital setting, prior to CT scanning, is uncertain. A large randomised controlled trial (CRASH-4) is planned to address this issue, but the economic justification for it has not been established. The aim of the analysis was to estimate the likelihood of tranexamic acid being cost-effective given current evidence, the treatment effects required for cost-effectiveness, and the expected value of performing further research. METHODS: An early economic decision model compared usual care for mild TBI with and without tranexamic acid, for adults aged 70 and above. The evaluation was performed from a UK healthcare perspective over a lifetime time horizon, with costs reported in 2020 pounds (GBP) and outcomes reported as quality-adjusted life years (QALYs). All analyses used a £20,000 per QALY cost-effectiveness threshold. RESULTS: In the base case analysis, tranexamic acid was associated with an incremental cost-effectiveness ratio of £4885 per QALY gained, but the likelihood of it being cost-effective was highly dependent on the all-cause mortality treatment effect. The value of perfect information was £22.4 million, and the value of perfect information for parameters that could be collected in a trial was £21.9 million. The all-cause mortality risk ratio for tranexamic acid and the functional outcomes following TBI had the most impact on cost-effectiveness. CONCLUSIONS: There is a high degree of uncertainty in the cost-effectiveness of tranexamic acid for older adults experiencing mild TBI, meaning there is a high value of performing future research in the UK. The value in a global context is likely to be far higher.
引用
- Williams J, Ker K, Roberts I, et al. A cost-effectiveness and value of information analysis to inform future research of tranexamic acid for older adults experiencing mild traumatic brain injury. Trials. 2022. PMID: 35505387. doi:10.1186/s13063-022-06244-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。